TY - JOUR
T1 - Vaccines and vaccination against tick-borne encephalitis
AU - Kollaritsch, Herwig
AU - Paulke-Korinek, Maria
AU - Holzmann, Heidemarie
AU - Hombach, Joachim
AU - Bjorvatn, Bjarne
AU - Barrett, Alan
N1 - Funding Information:
H Kollaritsch received research grants, fees for giving lectures, as well as support for attending advisory boards and international conferences from Baxter and Novartis. M Paulke-Korinek has received fees for speaking and support for attending international conferences from Novartis. J Hombach is a staff member of the WHO. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
PY - 2012/9
Y1 - 2012/9
N2 - Tick-borne encephalitis (TBE) is an emerging viral zoonosis and is endemic from Japan, China, Mongolia and Russia, to Central Europe and France. There is no specific treatment and TBE can be fatal. The four licensed prophylactic vaccines are produced according to WHO manufacturing requirements. Large clinical trials and postmarketing surveillance demonstrated safety and efficacy of the two European vaccines. The two Russian vaccines showed their effectiveness in daily use, but limited published data are available on controlled clinical trials. Vaccination recommendations in endemic areas vary significantly. In some countries, public vaccination programs are implemented. The WHO has recently issued recommendations on evidence-based use of TBE vaccines. However, more data are needed regarding safety, efficacy and long-term protection after vaccination.
AB - Tick-borne encephalitis (TBE) is an emerging viral zoonosis and is endemic from Japan, China, Mongolia and Russia, to Central Europe and France. There is no specific treatment and TBE can be fatal. The four licensed prophylactic vaccines are produced according to WHO manufacturing requirements. Large clinical trials and postmarketing surveillance demonstrated safety and efficacy of the two European vaccines. The two Russian vaccines showed their effectiveness in daily use, but limited published data are available on controlled clinical trials. Vaccination recommendations in endemic areas vary significantly. In some countries, public vaccination programs are implemented. The WHO has recently issued recommendations on evidence-based use of TBE vaccines. However, more data are needed regarding safety, efficacy and long-term protection after vaccination.
KW - epidemiology
KW - long-term protection
KW - prophylaxis
KW - tick-borne encephalitis
KW - vaccination
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=84869435167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869435167&partnerID=8YFLogxK
U2 - 10.1586/erv.12.86
DO - 10.1586/erv.12.86
M3 - Review article
C2 - 23151167
AN - SCOPUS:84869435167
SN - 1476-0584
VL - 11
SP - 1103
EP - 1119
JO - Expert review of vaccines
JF - Expert review of vaccines
IS - 9
ER -